 |
5 Diseases |  |
1 Trial |
|
1 Trial |  |
101 News |  |
- |||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment open, Trial completion date, Trial primary completion date: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Dec 10, 2023
P2/3, N=728, Recruiting, Sponsor: DiaMedica Therapeutics Inc
Active, not recruiting --> Recruiting
- ||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment change: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Nov 18, 2023
P2/3, N=728, Active, not recruiting, Sponsor: DiaMedica Therapeutics Inc
Active, not recruiting --> Recruiting N=339 --> 728
- |||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion date, Trial primary completion date: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Sep 8, 2023
P2/3, N=339, Active, not recruiting, Sponsor: DiaMedica Therapeutics Inc
N=339 --> 728 Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Dec 2025
- |||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion date, Trial primary completion date: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Jun 9, 2023
P2/3, N=364, Active, not recruiting, Sponsor: DiaMedica Therapeutics Inc
Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Dec 2025 Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Mar 2025
- ||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment closed: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Jul 28, 2022
P2/3, N=364, Active, not recruiting, Sponsor: DiaMedica Therapeutics Inc
Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Mar 2025 Recruiting --> Active, not recruiting
- ||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion, Trial completion date, Trial primary completion date: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Mar 31, 2022
P2, N=79, Completed, Sponsor: DiaMedica Therapeutics Inc
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022
- |||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment open: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Oct 26, 2021
P2/3, N=364, Recruiting, Sponsor: DiaMedica Therapeutics Inc
Recruiting --> Completed | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Mar 2022 Not yet recruiting --> Recruiting
- recombinant human tissue kallikrein (DM-199) / DiaMedica
[VIRTUAL] REDUX: A Multicenter, Open-Label Study of DM199 (Recombinant Human Tissue Kallikrein-1) in Patients with Stage 2 or 3 CKD () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_3934;
Conclusion These data provide clinical validation of the meaningful biologic activity of the recombinant KLK1 (DM199) and support the potential of achieving clinical benefit in patients with CKD. Enrollment is continuing in the AA/CKD and IgAN cohorts.
- |||||||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
New P2/3 trial: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) (clinicaltrials.gov) - Oct 3, 2021
P2/3, N=364, Not yet recruiting, Sponsor: DiaMedica Therapeutics Inc
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion date, Trial primary completion date: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Jun 16, 2021
P2, N=90, Recruiting, Sponsor: DiaMedica Therapeutics Inc
Enrollment is continuing in the AA/CKD and IgAN cohorts. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- recombinant human tissue kallikrein (DM-199) / DiaMedica
[VIRTUAL] REDUX: A Multicenter, Open-label Study of DM199 (recombinant human tissue kallikrein-1) in Patients with Stage II or III Chronic Kidney Disease () - Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_711;
CONCLUSION Treatments for patients with CKD and IgA nephropathy or type 2 diabetes do not routinely improve kidney function. Results from this Phase 2 study are expected to provide proof-of-concept for the effectiveness, safety, and tolerability of DM199 in specific subgroups of patients with Stage II or III CKD.
- recombinant human tissue kallikrein (DM-199) / DiaMedica
[VIRTUAL] Clinical Significance of Kallikrein Protein (KLK1) Levels Following DM199 in Patients with Diabetes and Chronic Kidney Disease () - Mar 2, 2021 - Abstract #NKFSCM2021NKF-SCM_531;
CONCLUSION Previous studies in patients with CKD and acute ischemic stroke demonstrated the safety and PK profile of DM199. This analysis provides data to support the rationale for using DM199 to increase KLK1 levels as a treatment in patient populations with CKD.
- recombinant human tissue kallikrein (DM-199) / DiaMedica
[VIRTUAL] Safety and Tolerability of Recombinant Human Tissue Kallikrein (DM199) in Acute Ischemic Stroke - The ReMEDy Randomized Clinical Trial (Featured/Live) - Feb 28, 2021 - Abstract #ISC2021ISC_158;
P2
DM199 did not significantly increase serious adverse effects versus placebo. The trial was not designed to assess efficacy and further evaluation of DM199 in a larger trial is warranted.
- ||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment change: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Aug 14, 2020
P2, N=90, Recruiting, Sponsor: DiaMedica Therapeutics Inc
The trial was not designed to assess efficacy and further evaluation of DM199 in a larger trial is warranted. N=60 --> 90
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion date, Trial primary completion date: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Jul 21, 2020
P2, N=60, Recruiting, Sponsor: DiaMedica Therapeutics Inc
N=60 --> 90 Trial completion date: Aug 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Dec 2020
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
#mecfs #MillionsMissing #MEAwareness #PwME MEActNet #BlackLivesMatter #StopRacism @NIHDirector @NINDSdirector @CDCDirector @NHSuk @CDCgov Racissm and ME: Healthcare Providers Must Believe People of Color! https://t.co/gLdMz99Wui (Twitter) - Jun 2, 2020
- recombinant human tissue kallikrein (DM-199) / DiaMedica
Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Subjects with Diabetes and Chronic Kidney Disease () - Mar 27, 2020 - Abstract #NKFCSM2020NKF_CSM_309;
The PK profile was dose-proportional and consistent with results from previous studies. DM199 single dose showed encouraging results with an increased eGFR and decreased UACR at 24 hours.
- ||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion: REMEDY: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Feb 5, 2020
P2, N=92, Completed, Sponsor: DiaMedica Therapeutics Inc
DM199 single dose showed encouraging results with an increased eGFR and decreased UACR at 24 hours. Active, not recruiting --> Completed
- recombinant human tissue kallikrein (DM-199) / DiaMedica
Changing patterns of hospitalized diabetic foot ulcer (DFU) in Thai patients - DFU as a canary in the coal mine? (Oral Poster Theatre 5) - Nov 20, 2019 - Abstract #IDF2019IDF_864;
DFUs were classified into neuropathic wounds (38.0%), ischemic wounds (2.6%), and mixed type wounds (59.4%). The median length of stay was 8 (range 1-104) days.
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment closed: REMEDY: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Nov 16, 2019
P2, N=92, Active, not recruiting, Sponsor: DiaMedica Therapeutics Inc
The median length of stay was 8 (range 1-104) days. Recruiting --> Active, not recruiting
- ||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment open: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Nov 15, 2019
P2, N=60, Recruiting, Sponsor: DiaMedica Therapeutics Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | recombinant human tissue kallikrein (DM-199) / DiaMedica
New P2 trial: Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX) (clinicaltrials.gov) - Oct 11, 2019
P2, N=60, Not yet recruiting, Sponsor: DiaMedica Therapeutics Inc
- | recombinant human tissue kallikrein (DM-199) / DiaMedica
Trial completion: Study to Assess PK, Safety and Tolerability in Patients With DM and CKD (clinicaltrials.gov) - Jul 31, 2019
P1, N=33, Completed, Sponsor: DiaMedica Therapeutics Inc
Not yet recruiting --> Recruiting Recruiting --> Completed
- | recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment change, Trial completion date, Trial primary completion date: REMEDY: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Jul 17, 2019
P2, N=100, Recruiting, Sponsor: DiaMedica Therapeutics Inc
Recruiting --> Completed N=60 --> 100 | Trial completion date: Jun 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment open: Study to Assess PK, Safety and Tolerability in Patients With DM and CKD (clinicaltrials.gov) - Feb 20, 2019
P1, N=32, Recruiting, Sponsor: DiaMedica Therapeutics Inc
N=60 --> 100 | Trial completion date: Jun 2019 --> Jan 2020 | Trial primary completion date: Apr 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- || recombinant human tissue kallikrein (DM-199) / DiaMedica
New P1 trial: Study to Assess PK, Safety and Tolerability in Patients With DM and CKD (clinicaltrials.gov) - Jan 7, 2019
P1, N=32, Not yet recruiting, Sponsor: DiaMedica Therapeutics Inc
- |||| recombinant human tissue kallikrein (DM-199) / DiaMedica
Enrollment open, Trial initiation date: REMEDY: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Feb 12, 2018
P2, N=60, Recruiting, Sponsor: DiaMedica USA Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Jan 2018
- ||||| recombinant human tissue kallikrein (DM-199) / DiaMedica
New P2 trial: REMEDY: Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke (clinicaltrials.gov) - Sep 25, 2017
P2, N=60, Not yet recruiting, Sponsor: DiaMedica USA Inc.
- | Trial completion, Enrollment change: An Open Label, Phase 1b, Ascending Dose Study of DM199 (clinicaltrials.gov) - Apr 26, 2017
P1b, N=36, Completed, Sponsor: DiaMedica USA Inc.
Not yet recruiting --> Recruiting | Initiation date: Nov 2017 --> Jan 2018 Recruiting --> Completed | N=12 --> 36
- Enrollment open: An Open Label, Phase 1b, Ascending Dose Study of DM199 (clinicaltrials.gov) - Sep 30, 2016
P1b, N=12, Recruiting, Sponsor: DiaMedica USA Inc.
Recruiting --> Completed | N=12 --> 36 Not yet recruiting --> Recruiting
- | New P1 trial: An Open Label, Phase 1b, Ascending Dose Study of DM199 (clinicaltrials.gov) - Aug 15, 2016
P1b, N=12, Not yet recruiting, Sponsor: DiaMedica USA Inc.
- |||| Trial completion, Enrollment change: A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=98, Completed, Sponsor: DiaMedica USA Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=76 --> 98
- ||||| New P1/2 trial: A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients (clinicaltrials.gov) - May 1, 2013
P1/2, N=76, Recruiting, Sponsor: DiaMedica USA Inc.